Concurrence of TDP-43, Tau and Alpha-synuclein Pathology in Brains of Alzheimer's Disease and Dementia with Lewy Bodies
Authors
Affiliations
TAR-DNA-binding protein 43 (TDP-43) has been identified as a major component protein of ubiquitin-positive inclusions in brains from patients with frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis. To obtain the precise prevalence of TDP-43 pathology in neurodegenerative disorders, we examined brains from patients with tauopathies and synucleinopathies as well as FTLD-U using immunohistochemical analysis. Consequently, TDP-43-positive inclusions within neurons and oligodendroglia were found in brains from patients with Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) in addition to FTLD-U, but not with Parkinson's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration or FTDP-17. The amygdala and hippocampus that were vulnerable to tau or alpha-synuclein pathology demonstrated more severe TDP-43 pathology in AD and DLB cases than in FTLD-U cases. In contrast, in the frontal cortex and basal ganglia that were vulnerable to TDP-43 pathology in FTLD-U, TDP-43 pathology was not observed in AD and DLB cases. Thus, the neuroanatomical distribution of TDP-43 pathology in AD and DLB cases was obviously different from that in FTLD-U cases. Furthermore, a subset of TDP-43-positive inclusions co-existed with neurofibrillary tangles (NFTs) or Lewy bodies (LBs) in the same neurons. Upon double-immunofluorescent labeling analysis, TDP-43 was hardly superimposed with tau, while TDP-43 was partially superimposed with alpha-synuclein, suggesting that neither NFTs nor LBs themselves show TDP-43 immunoreactivity and that TDP-43 pathology found in this study may be related in some way to AD and LB pathology. This study will provide a more in-depth understanding of the various pathogenic pathways leading to neurodegenerative disorders.
Yang C, Lee G, Hao L, Hu F Commun Biol. 2025; 8(1):315.
PMID: 40011708 PMC: 11865606. DOI: 10.1038/s42003-025-07752-2.
The Regulation of TDP-43 Structure and Phase Transitions: A Review.
Liu Y, Xiang J, Gong H, Yu T, Gao M, Huang Y Protein J. 2025; .
PMID: 39987392 DOI: 10.1007/s10930-025-10261-0.
Wisse L, Wuestefeld A, Murray M, Jagust W, La Joie R Alzheimers Dement. 2025; 21(2):e14582.
PMID: 39985478 PMC: 11846482. DOI: 10.1002/alz.14582.
White matter hyperintensities and TDP-43 pathology in Alzheimer's disease.
Carlos A, Weigand S, Pham N, Petersen R, Jack Jr C, Dickson D Alzheimers Dement. 2025; 21(2):ealz14516.
PMID: 39821594 PMC: 11851154. DOI: 10.1002/alz.14516.
Gawor K, Tome S, Vandenberghe R, Van Damme P, Vandenbulcke M, Otto M Brain Commun. 2024; 6(6):fcae442.
PMID: 39659977 PMC: 11631359. DOI: 10.1093/braincomms/fcae442.